Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 23, 2006

View Archived Issues

Recent data on HDAC inhibitors in neurological conditions

Preclinical data on actively investigated KSP inhibitor from GSK

Gantacurium pharmacodynamics assessed in phase II trial

Study reveals phenoxodiol effects, mechanism in prostate cancer

Cobra signs CRADA with U.S. Navy for ORT-VAC based malaria vaccine

Rencarex completes phase II study in combination interferon alpha-2a

Phase II study of MF-101 for menopausal symptoms completes enrollment

Enrollment complete in first stage of phase II ALS trial of ALS-08

Auxilium discontinues TestoFilm, reallocates resources to AA-4500

NIH releases strategic plan to guide type 1 diabetes research

SIGA-246 gives 100% protection against human smallpox virus in primate trial

Positive phase III findings for Transacin in postherpetic neuralgia

Genmab updates pipeline progress and future plans

Merck KGaA and Glenmark sign agreement for DPP-IV inhibitor GRC-8200

Bayer and Regeneron to collaborate on VEGF Trap-Eye

Recent patents describe novel agents for anxiety, depression, psychosis, etc.

Recent patents disclose new antiinfective agents

Novel treatment strategies for cancer covered in recent patent literature

Compugen selects three new potential therapeutic candidates

Novel sigma receptor antagonists combat cocaine-induced behavioral toxicity

Preclinical data on Merck's novel CB1 agonist MK-0364 reported at the SfN meeting

Differential modulation of mGluR5 activity yields therapeutic potential in CNS disorders

Seroquel SR filed for approval in Canada, E.U.

Adrovance recommended for approval in E.U.

European CHMP issues positive opinion on Diacomit submission

Tandemact recommended for approval in E.U.

Europe's CHMP recommends Hycamtin for new indication

Positive opinion handed down in Europe for new Glivec indication

Aldara recommended for approval for actinic keratosis in Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...